Background: Suppression of neoangiogenesis and pegylated liposomal doxorubicin (PLD) each contribute to the management of platinum-resistant/refractory ovarian cancer. The aim of this study is to test the combination of bevacizumab and PLD in women with resistant or refractory ovarian cancer.
introduction
The abnormal permeability of tumor blood vessels and the absence of lymphatics in tumors versus normal tissues lead to increased drug localization of large molecules with long intravascular half-life, such as pegylated liposomal doxorubicin (PLD), despite the greater interstitial pressure present in tumors [1] [2] [3] . This enhanced retention confers to PLD an improved therapeutic index against several tumor xenografts compared with doxorubicin [4] . The antitumor activity of PLD against platinum-refractory epithelial ovarian cancer (EOC) was initially observed in phase I studies [5] , and confirmed in phase II studies [6] . Responses to PLD preferably occur in disease that is not bulky [6] . The randomized study comparing PLD with topotecan established the preferred role of PLD, with the most significant difference noted in platinum-sensitive disease [7] . Typically, several cycles are required for maximum response, and some patients on continued treatment have prolonged stable disease. Progression-free survival (PFS) is around 4-5 months with an overall survival (OS) of about 1 year. Bevacizumab, an antibody to vascular endothelial growth factor (VEGF)-A, has also shown activity in patients with platinum-resistant EOC [8, 9] . Bevacizumab prevents the formation of the tumorigenic vasculature responsible for increased vascular permeability and interstitial pressure in tumors. Thus, the hypothesis is that bevacizumab will enhance the retention of PLD [10] in tumors, therefore improving antitumor effects. The present study tests this hypothesis in patients with platinum-resistant EOC.
A phase I of the combination was not deemed necessary in view of the conservative doses of PLD chosen for study and the extensive experience with bevacizumab in a number of combinations, including doxorubicin. The aggravation of anthracycline cardiac toxic effects has been noted when combined to bevacizumab, thus we introduced baseline left ventricular ejection fraction assessments and frequent monitoring during follow-up.
patients and methods
This is a classical phase II study of the combination of PLD and bevacizumab in patients with platinum-resistant EOC. In this two-center open-label study (NCT00945139 and NCT00846612), PLD and bevacizumab were administered every 3 weeks, except for the first cycle when PLD was administered as a single agent. The study was approved by the Institutional Review Boards of both institutions and all patients signed a written consent. The primary end point was PFS. The secondary endpoints were OS, the incidence of adverse events of the combination, the overall response rate (ORR), and the clinical benefit rate (CBR) (ORR + patients with stable disease = CBR). MUGA scans and CT-scans of abdomen and pelvis were done every three cycles and after completion of study treatment. Additional imaging was obtained at varying intervals for clinical reasons after going off-study. The response and progression were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 and Gynecologic Cancer Intergroup Committee (GCIC) criteria including CA-125 measurements [11] . The dose of PLD was 30 mg/m 2 and that of bevacizumab was 15 mg/kg (beginning on cycle 2) every 3 weeks. PLD dose could be decreased twice by 5 mg/m 2 each time. Bevacizumab was either given or withheld, according to the adverse events. Common Terminology Criteria for Adverse Events version 3 was used. Supplementary Table S1 (available at Annals of Oncology online) shows the dose/schedule adjustments. If one drug was discontinued for safety reasons, the patient could continue the study receiving the other drug as a single agent. Dose delays due to toxicity by 1 week increments until recovery to grade 1 or less were required for non-hematological toxic effects of grade 2 or greater persisting at the time of scheduled retreatment. Patients requiring more than 8 week dosing delays to meet these criteria were to be taken off study.
statistical considerations
Based on the gynecologic oncology group (GOG) outcomes in recent EOC studies for platinum-resistant recurrences, the null hypothesis set a PFS of 25% at 6 months without addition of bevacizumab [12] . The alternative hypothesis proposed a PFS rate of 50% at 6 months, in order to reject the null hypothesis. A one-sided log-rank test with a sample size of 44 assessable patients achieves an 80% power at a 5% type I error level to reject the null hypothesis. This is not an intent-to-treat analysis, as the clinical objectives are to establish feasibility for possible further evaluation. The PFS and OS curves were determined using the Kaplan-Meier computation with 95% confidence intervals (CI).
results

patient population
Of 62 patients screened, 46 were treated. Fourteen patients were not eligible and two refused participation. The patient demographics are listed in Table 1 . There were 35 Whites, 7 Hispanics, 2 Native Americans, and 2 Blacks. The median age was 64 years (range 34-86 years). The median ECOG performance status was 0 (range 0-1). Histological subtypes were papillary serous (33), adenocarcinoma not otherwise specified (NOS) (6), endometrioid (4), clear cell (2) , and mixed mullerian tumor with an epithelial component at recurrence (1) . Two patients received only one cycle of PLD and no bevacizumab: one had an early progression and was referred to hospice, and the other one was found to have an aortic aneurysm and was taken off study. They are, therefore, excluded from the overall efficacy and toxicity evaluations of the combination. Thus, 44 patients who received bevacizumab are assessable. The median number of prior chemotherapy regimens was 2 (range 1-3); with one exception who received an epothilone, all patients had received a platinum and taxane regimen as induction. Twenty-four patients received a second treatment with a platinum doublet: 11 with a taxane, 9 with gemcitabine or 4 with other drugs; 6 also received regimens containing experimental tyrosine kinase inhibitors (3), hormones (1), or palliative radiotherapy (1). Five patients had received either bevacizumab or placebo in a previous study (GOG 218 [13] and OCEANS study [14] ).
PFS and OS
PFS, the primary endpoint, was assessable for 40 patients by CA-125 (GCIC criteria) and for 43 patients by RECIST criteria ( Figure 1 ). The median time to progression by GCIC criteria was 6.6 months (range 1-24.6 months; 95% CI 5.5-8.7) and by RECIST criteria, 7.8 months (range 2-13.3 months; 95% CI 6.4-9.7) ( Figure 1 ). The median OS was 33.2 months (range 3-40+ months; 95% CI 18.8 not applicable). There were no treatment-related deaths.
ORR
Forty-three patients are assessable for response. One patient could not be assessed because she went off study for encephalopathy (for details, see below). Her scans were not repeated after baseline and only one CA-125 value obtained One patient was accepted after a 12-month interval because she had developed allergy to platinum agents. ECOG, eastern cooperative oncology group; NOS, not otherwise specified.
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after baseline showed a 50% decrease. By RECIST criteria, the ORR was found to be 30% and the CBR 86% with a median time to response of 9 weeks (range 9-24 weeks). By GCIC criteria [11] , the ORR was found to be 50% with a median time to response of 6 weeks (range 3-18 weeks). It is worth noting that there was an initial increase of CA-125 seen after the first course (PLD only), before a decrease to the stated response rates (supplementary Table S2 , available at Annals of Oncology online) ( Table 2) .
adverse events
There were 315 cycles of treatment administered to 44 patients, [6.9 cycles per patient (range 2-18 cycles)].
hematological toxicity
Only grades 1 and 2 neutropenia, anemia, and thrombocytopenia were observed in 1, 5, and 3%, and 4, 2, and 1%, respectively. One patient, who achieved a partial response after three cycles, abruptly developed symptoms of a hemolytic/uremic syndrome at cycle 7 with grade 3 neutropenia, anemia, and thrombocytopenia. This patient experienced difficult-to-control hypertension after two cycles requiring both delay in bevacizumab administration and a dose reduction of PLD. Four weeks after the seventh cycle, she was admitted for a hemolytic/uremic syndrome with elevated serum creatinine and lactate dehydrogenase (LDH). With plasmapheresis, hematological and non-hematological changes totally reversed. The relationship to bevacizumab is probable. 
non-hematological toxicity
All non-hematological adverse events are shown in Table 3 .
The non-highlighted adverse events are those that are most likely related to disease and/or prior chemotherapy; these included asthenia (52%), moderate gastrointestinal symptoms (up to 36% of patients), myalgia, mild (grade 1) non-specific skin complaints, and transient fever with mild infections, except for three patients with a grade 3 tooth abscess. No firm attribution is made on these common events, although one cannot exclude that the study drugs were in part responsible.
The dark gray shade adverse events were deemed related to bevacizumab. Hypertension and headaches were noted in about 46 and 41% of patients, respectively. One patient developed a grade 4 central neurological syndrome, possibly a reversible posterior leukoencephalopathy syndrome, related to the first dose of bevacizumab with cognitive disturbance, including ataxia, slurred speech, memory impairment, rightsided hemiparesis, and tremor. She was removed from the study. Grade 1 epistaxis was noted in 20% of patients. Renal impairment and proteinuria were observed in 11 and 7% of patients, respectively (including the patient with the hemolytic/ uremic syndrome). No perforations and only one wound dehiscence were observed.
The adverse events highlighted in light gray formed an emerging panel that might be related to the combination. All patients recovered after discontinuation of treatment, but not always to baseline. In 7 of 44 patients (16%), there was an asymptomatic decrease of ejection fraction (EF) (median EF decrease, 21.4%; range 13.6-45%). Skin and mucosal sideeffects included (i) palmar plantar erythroderma (PPE) in 23 (52%) patients, with blisters in 13 (30%); (ii) mucositis in 64% of patients which included esophageal and pharyngeal erosions in three patients each and more mildly causing dysphagia or dyspepsia in 12 patients; and (iii) rash either desquamating or with pruritus in 50% of patients with related hyperpigmentation noted in 18% of patients. Prevention with steroids was attempted, but the amount of steroids to help decrease these symptoms led to corticosteroid complications such as hyperglycemia (data not shown).
Bearing an uncertain relationship are other findings highlighted in very light gray. Sensory neuropathy was observed in 25% of patients, but all of them had been exposed to paclitaxel. Respiratory problems, including cough or dyspnea, were seen in 20%. Hyponatremia was measured in 18%. Other possible adverse events (<10%) included hypokalemia, hypocalcemia, dry eyes, and voice alteration.
dose modifications for PLD
First dose reduction was by 17%, and second one by 33%. Sixteen patients required one dose reduction of PLD, then two patients had a second dose reduction. In one patient the dose was reduced by 33% immediately. The percentage of patients requiring a PLD dose reduction was thus 39% because of PPE (14 patients), hypertension (2 patients), and neutropenia Table S3 , available at Annals of Oncology online). The main reasons were PPE (15 delays), hypertension (3 delays), and mucositis, neutropenia, thrombocytopenia, fatigue (1 delay each). Two patients withdrew consent after six cycles, one in partial response and one with stable disease at discontinuation. Nine patients stopped all treatment for persistent adverse events and one after she had an accidental bone fracture requiring surgery (supplementary Table S4 , available at Annals of Oncology online). Thirteen patients discontinued treatment for progression before they received the planned eight cycles. Nineteen patients completed the eight planned cycles (8 of them received > 8 cycles).
discussion
Bevacizumab is approved in combination with chemotherapy for the treatment of colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, and glioblastoma multiforme [15, 16] . Known side-effects of VEGF inhibition include hypertension, wound dehiscence, bleeding, thromboembolic events, bowel perforation, and pneumothorax [17] . In a recent meta-analysis of 16 randomized trials enrolling 10 217 various cancer patients (none with ovarian cancer), the incidence of fatal adverse events with bevacizumab was 2.5% (95% CI, 1.7-3.9%), with a relative risk of drugrelated death of 1.46 (95% CI 1.09-1.94; P = 0.01) [18] . This association was more significant when bevacizumab was combined with taxane or platinum (RR, 3.49; 95% CI, 1.82-6.66). In women with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancers the addition of bevacizumab to carboplatin and paclitaxel increases PFS by 3-4 months with no OS benefit [13, 14, 19] In women with platinum-refractory ovarian cancer, single agent bevacizumab administered intravenously at a dose of 15 mg/kg IV every 3 weeks yields PFS of 4-5 months, similar to that of any chemotherapy single agent [8, 9] . The response rate varies between 16% and 21%. Grades 3 and 4 gastrointestinal perforation, hypertension, and proteinuria are seen in about 10% of patients, and hemorrhage, fistula, wound-healing complications, and thromboembolic events in 5% or less. Bevacizumab was tested in combination with low-dose cyclophosphamide in 70 patients with recurrent disease. Bevacizumab dose was 10 mg/kg IV on days 1, 8, 15 and then every 2 weeks with cyclophosphamide at 50 mg orally per day. The response rate was 24% and the CBR 80% in 29 assessable patients. The median PFS and OS were 7.2 and 16.9 months, respectively. The toxicity profile did not seem different than after administration of bevacizumab as single agent [20] . In a study of nab-paclitaxel with bevacizumab in 48 platinumresistant patients, nab-paclitaxel was administered weekly at 100 mg/m 2 IV on days 1, 8, 15 with bevacizumab 10 mg/kg IV given on days 1 and 15 every 28 days, until progression. The median PFS and OS were 8.3 and 16.5 months, respectively. The partial response for the 39 patients who have completed this study to date was 46.1% with a CBR of 76.9% [21] .
This new study of the combination of PLD and bevacizumab confirms the contribution of bevacizumab in extending the PFS and perhaps OS in patients with platinum-refractory disease. The primary endpoint for the combination was met; the PFS exceeded 6 months, both by RECIST and GCIC criteria. The secondary endpoints of survival and response were also met; the median survival was 33.2 months and the ORR was 30.2% with a striking CBR of over 80%. When compared with other studies of chemotherapy in patients with platinum-resistant ovarian cancer (Table 4) , both survivals and response rates are substantially higher with this new combination. This increment in PFS approximates the PFS advantage seen in both first-and second-line platinumsensitive ovarian cancer randomized studies. These very positive outcomes, however, are mitigated by the adverse events observed during this study. Synergistic toxic effects were observed as skin and mucosal manifestations, uncovering a panel of events that are usually not observed with the same frequency or intensity after treatment by each agent alone. These are highlighted in gray in Table 3 . Most worrisome is the decrease in cardiac function (16%), despite the absence of symptoms. Perhaps relevant, a study of doxorubicin and bevacizumab in patients with sarcoma was also deemed too toxic because of cardiac events that included symptomatic cardiac failure in some [22] . In the current study, pharyngeal and esophageal ulcerations and skin blistering were dramatic side-effects, suggesting enhancement of the usual PLD mucositis and PPE by bevacizumab. Generalized skin rashes were common and led to frequent desquamation and hyperpigmentation. This dermatomucosal toxicity caused significant complications of dysphagia, pain, and distress to patients leading to treatment interruptions and dose reductions to help resolve symptoms (supplementary Table S3 , available at Annals of Oncology online). The analysis of adverse events data also suggests possible synergistic effects leading to the aggravation of peripheral neuropathy respiratory/pulmonary and voice changes, and metabolic abnormalities such as hypokalemia and hyponatremia.
Because of this panel of toxic effects, this combination is not recommended in patients with platinum-and taxane-resistant disease outside the confines of a clinical study designed to prove a survival advantage over other regimens, such as the AURELIA study (NCT00976911). Certainly, it should not be used as part of first-line treatment that would include PLD [23] because of the toxicity profile we observed during this trial and the lack of evidence that the use of bevacizumab in the frontline setting produces any superior survival benefit relative to the one obtained later during the course of the disease. Alternate schedules and dosing of bevacizumab and PLD may yield a lower toxicity profile with a maintained benefit. The data analysis of a weekly schedule is currently not mature, but promising [24] .
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